Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
Background: Cell and gene therapies are associated with uncertainty around their value claims at launch due to limitations of supporting clinical data; furthermore, their high costs present affordability issues for payers. Outcomes-based reimbursement can reduce payer decision uncertainty and improv...
Main Authors: | Jesper Jørgensen, Laura Mungapen, Panos Kefalas |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Journal of Market Access & Health Policy |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20016689.2019.1573164 |
Similar Items
-
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
by: Jesper Jørgensen, et al.
Published: (2018-01-01) -
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
by: Panos Kefalas, et al.
Published: (2018-01-01) -
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
by: Jesper Jørgensen, et al.
Published: (2019-01-01) -
Advances in Composite Construction in the UK
by: Lam, Dennis
Published: (2013) -
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
by: Jesper Jørgensen, et al.
Published: (2020-01-01)